ADAM10 and neoplasm: Importantly, 8C7 preferentially bound ADAM10 from tumours versus that from normal tissues, indicating enhanced ADAM10 activity in tumours, and therefore the potential of 8C7 to be developed as a tumour-targeting agent [20].